Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
RedHill Biopharma Ltd. shows accelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue +59% YoY in Q2 FY2025.
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 2d ago
RDHL's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on RDHL.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for RedHill Biopharma Ltd. (RDHL) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
RDHL's AI investment thesis
Upgrade to Premium for RDHL's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$0.51
Market cap
$25.74B
Profitable
No
Revenue $4.08M
Net income
$-4.13M
FY Sep 12, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for RedHill Biopharma Ltd. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow RedHill Biopharma Ltd. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.